Skip to content
value.today

Juno Therapeutics, Inc.

🇺🇸 Seattle, Washington, USABiotechnologyFounded 2013

Formerly FC Therapeutics, Inc.

Total raised
$152 M
4 rounds on record
Latest round
$31 M
Sep 2017
First round on record
Dec 2013
Today
Private
No later event on record

Funding rounds

4 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Juno Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Sep 2017$31 MNo. 4$10 to $50 million

Juno Therapeutics, Inc.: Raise no. 4, Sep 2017

Investors in this round

1 investor had bought by the notice of Oct 5, 2017: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 9 investors are named for Juno Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$31 M of $31 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(c): may be advertised publicly; every buyer must be a verified accredited investor
Meant to last
a year or less
Issuer's revenue
$25 million to $100 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bernard J. Cassidy · Executive Officer
  • Hans Bishop · Executive Officer, Director, Promoter
  • Robert Azelby · Executive Officer
  • Steven Harr · Executive Officer
  • Sunil Agarwal · Executive Officer
  • Anthony J. Evnin · Director
  • Hal J. Barron · Director
  • Howard J. Pien · Director
  • Jay J. Flatley · Director
  • Mary Agnes Wilderotter · Director
  • Richard J. Klausner · Director, Promoter
  • Robert J. Nelsen · Director, Promoter
  • Rupert Agnes Vessey · Director
  • Thomas Agnes Daniel · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “See the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 22, 2017.”

Signed by Bernard J. Cassidy, General Counsel & Secretary. Source: SEC Form D, newest notice filed Oct 5, 2017. Read the notice at the SEC.

equitySEC
Jun 2015$899 MAmount not plausible as filed$250 million to $1 billion

Juno Therapeutics, Inc.: Private sale, Jun 2015

Investors in this round

2 investors had bought by the notice of Jun 29, 2017: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 9 investors are named for Juno Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$899 M (amount offered: indefinite)
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(c): may be advertised publicly; every buyer must be a verified accredited investor
Meant to last
more than a year
Issuer's revenue
$5 million to $25 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bernard J. Cassidy · Executive Officer
  • Hans Bishop · Executive Officer, Director, Promoter
  • Robert Azelby · Executive Officer
  • Steven Harr · Executive Officer
  • Sunil Agarwal · Executive Officer
  • Anthony J. Evnin · Director
  • Hal J. Barron · Director
  • Howard J. Pien · Director
  • Jay J. Flatley · Director
  • Mary Agnes Wilderotter · Director
  • Richard J. Klausner · Director, Promoter
  • Robert J. Nelsen · Director, Promoter
  • Rupert Agnes Vessey · Director
  • Thomas Agnes Daniel · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “See the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on June 29, 2015, March 28, 2016, and March 31, 2017, respectively.”

Signed by Bernard J. Cassidy, General Counsel & Secretary. Source: SEC Form D and 2 amendments, newest notice filed Jun 29, 2017. Read the notice at the SEC.

equity, optionsSEC
Aug 2014$86 MNo. 3$50 to $250 million

Juno Therapeutics, Inc.: Raise no. 3, Aug 2014

Investors in this round

22 investors had bought by the notice of Aug 14, 2014: 22 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 9 investors are named for Juno Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$86 M of $134 M offered; $48 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bernard Cassidy · Executive Officer
  • Hans Bishop · Executive Officer, Director, Promoter
  • Mark Frohlich · Executive Officer
  • Steven Harr · Executive Officer
  • Anthony Evnin · Director
  • Howard Pien · Director
  • Marc Tessier-Lavigne · Director
  • Richard Klausner · Director, Promoter
  • Robert Nelsen · Director, Promoter

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Hans Bishop, Chief Executive Officer. Source: SEC Form D, newest notice filed Aug 14, 2014. Read the notice at the SEC.

equity, optionsSEC
Apr 2014$28 MNo. 2$10 to $50 million

Juno Therapeutics, Inc.: Raise no. 2, Apr 2014

Investors in this round

34 investors had bought by the notice of May 8, 2014: 34 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 9 investors are named for Juno Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$28 M of $97 M offered; $69 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Hans Bishop · Executive Officer, Director, Promoter
  • Anthony Evnin · Director
  • Howard Pien · Director
  • Marc Tessier-Lavigne · Director
  • Rick Klausner · Director, Promoter
  • Robert Nelsen · Director, Promoter

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Hans Bishop, Chief Executive Officer. Source: SEC Form D, newest notice filed May 8, 2014. Read the notice at the SEC.

equity, optionsSEC
Dec 2013$7 MNo. 1$2 to $10 million

Juno Therapeutics, Inc.: Raise no. 1, Dec 2013

Investors in this round

21 investors had bought by the notice of Dec 26, 2013: 21 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 9 investors are named for Juno Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$7 M of $7 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Hans Bishop · Executive Officer, Director, Promoter
  • Larry Corey · Director
  • Rick Klausner · Director, Promoter
  • Robert Nelsen · Director, Promoter

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Hans Bishop, Ceo. Source: SEC Form D, newest notice filed Dec 26, 2013. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Juno Therapeutics, Inc. had revenue between $25 million and $100 million when it filed its newest notice of a funding round (Oct 2017).

    SEC Form D (revenue range) · Oct 2017

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Oct 2017

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

9 named in official filings. Open an investor to see everything it has backed.

Investors in Juno Therapeutics, Inc.
InvestorKindAmountRoundRoleSource
Arch Venture Fund VII LPVenture capitalnot statednot statedHeld Series A, A-2 and B preferred stock, 10% owner (Form 3, 2014)SEC Form 3
ARCH Venture Partners VII, LLCVenture capitalnot statednot statedHeld Series A, A-2 and B preferred stock, 10% owner (Form 3, 2014)SEC Form 3
ARCH Venture Partners VII, L.P.Venture capitalnot statednot statedHeld Series A, A-2 and B preferred stock, 10% owner (Form 3, 2014)SEC Form 3
CL Alaska, L.P.Fund or asset managernot statednot statedHeld Series A, A-2 and B preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Crestline Investors, Inc.Fund or asset managernot statednot statedHeld Series A, A-2 and B preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Crestline Management, L.P.Fund or asset managernot statednot statedHeld Series A, A-2 and B preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Crestline SI (GP), L.P.Fund or asset managernot statednot statedHeld Series A, A-2 and B preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Howard H. PienPersonnot statednot statedHeld Series A-2 preferred stock, director (Form 3, 2014)SEC Form 3
Marc Tessier-LavignePersonnot statednot statedHeld Series A-2 preferred stock, director (Form 3, 2014)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 34 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Juno Therapeutics, Inc.
NameRoleNamed in
Bernard J. CassidyExecutive officerOct 2017
Hans BishopExecutive officerOct 2017
Robert AzelbyExecutive officerOct 2017
Steven HarrExecutive officerOct 2017
Sunil AgarwalExecutive officerOct 2017
Hyam LevitskyExecutive officerJul 2016
Mark FrohlichExecutive officerJul 2015
Bernard CassidyExecutive officerAug 2014
Anthony J. EvninDirectorOct 2017
Hal J. BarronDirectorOct 2017
Hans BishopDirectorOct 2017
Howard J. PienDirectorOct 2017
Jay J. FlatleyDirectorOct 2017
Mary Agnes WilderotterDirectorOct 2017
Richard J. KlausnerDirectorOct 2017
Robert J. NelsenDirectorOct 2017
Rupert Agnes VesseyDirectorOct 2017
Thomas Agnes DanielDirectorOct 2017
Marc J. Tessier-LavigneDirectorJul 2016
Anthony EvninDirectorAug 2014
Howard PienDirectorAug 2014
Marc Tessier-LavigneDirectorAug 2014
Richard KlausnerDirectorAug 2014
Robert NelsenDirectorAug 2014
Rick KlausnerDirectorMay 2014
Larry CoreyDirectorDec 2013
Hans BishopPromoterOct 2017
Richard J. KlausnerPromoterOct 2017
Robert J. NelsenPromoterOct 2017
Mark FrohlichPromoterJul 2015
Richard KlausnerPromoterAug 2014
Robert NelsenPromoterAug 2014
Rick KlausnerPromoterMay 2014